HC Wainwright Starts Theriva (TOVX) at Buy on Undervalued Oncolytic Virus Platform and Advancing VCN-01 Pancreatic Cancer ProgramTip Ranks·Aug 12 at 12:55 PMTOVX-0.87%
Theriva Biologics, Inc. 2026: Revenue ($3.35M), Net income ($3.22M), EPS ($0.07) — 10-Q SummaryTradingView·Aug 11 at 07:21 AMTOVX-0.87%
Theriva Biologics doses first patient in VIRAGE2 Phase 2a trial of VCN-01 for metastatic pancreatic cancerPUBT·Aug 6 at 07:13 AMTOVX-0.87%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·Jul 7 at 07:05 AMCOSM+5.52%BJDX-0.94%
Theriva Biologics wins Spanish regulator clearance for VIRAGE2 VCN-01 pancreatic cancer trialPUBT·Jul 7 at 07:01 AMTOVX-0.87%
Theriva Biologics shares are trading higher after the company announced the publication of clinical, translational results from VCN-01's Phase 1 clinical trial in Head & Neck Squamous Cell Carcinoma in Clinical Cancer Research journal.benzinga_article·Jun 11 at 07:46 AMTOVX-0.87%
Alliance Global Partners Sticks to Its Buy Rating for Theriva Biologics (TOVX)Tip Ranks·May 6 at 06:38 AMTOVX-0.87%IBBQ-0.30%
Theriva Q1 Net Loss Narrows; Plans Dosing Feasibility Study Of VCN-01 In H2,2026;Stock Downnasdaq·May 6 at 04:35 AMTOVX-0.87%ARKG-1.96%
